{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T06:26:34Z","timestamp":1680071194164},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas Pharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The vascular adhesion protein-1 (VAP-1) inhibitor ASP8232 reduces albuminuria in patients with type 2 diabetes and chronic kidney disease. A mechanism-based model was developed to quantify the effects of ASP8232 on renal markers from a placebo-controlled Phase 2 study in diabetic kidney disease with 12\u00a0weeks of ASP8232 treatment. The model incorporated the available pharmacokinetic, pharmacodynamic (plasma VAP-1 concentration and activity), serum and urine creatinine, serum cystatin C, albumin excretion rate, urinary albumin-to-creatinine ratio, and urine volume information in an integrated manner. Drug-independent time-varying changes and different drug effects could be quantified for these markers using the model. Through simulations, this model provided the opportunity to dissect the relationship and longitudinal association between the estimated glomerular filtration rate and albuminuria and to quantify the pharmacological effects of ASP8232. The developed drug-independent model may be useful as a starting point for other compounds affecting the same biomarkers in a similar time scale.<\/jats:p>","DOI":"10.1007\/s10928-020-09716-x","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T20:02:42Z","timestamp":1600113762000},"page":"21-38","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease"],"prefix":"10.1007","volume":"48","author":[{"given":"Sven","family":"Hoefman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelleke","family":"Snelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn","family":"van Noort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Garcia-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Onkels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias E.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten R.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"9716_CR1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10681014","author":"LF Fried","year":"2015","unstructured":"Fried LF, Lewis J (2015) Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/CJN.10681014","journal-title":"Clin J Am Soc Nephrol"},{"key":"9716_CR2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01610215","author":"LF Fried","year":"2015","unstructured":"Fried LF, Lewis J (2015) Rebuttal of the pro view: albuminuria is an appropriate therapeutic target in patients with CKD. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/CJN.01610215","journal-title":"Clin J Am Soc Nephrol"},{"key":"9716_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2213-8587(18)30289-4","volume":"8587","author":"D de Zeeuw","year":"2018","unstructured":"de Zeeuw D, Renfurm RW, Bakris G et al (2018) Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diab Endocrinol 8587:1\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(18)30289-4","journal-title":"Lancet Diab Endocrinol"},{"key":"9716_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.03.041","author":"HY Li","year":"2009","unstructured":"Li HY, Wei JN, Lin MS et al (2009) Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta. https:\/\/doi.org\/10.1016\/j.cca.2009.03.041","journal-title":"Clin Chim Acta"},{"key":"9716_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051143","author":"F Boomsma","year":"1999","unstructured":"Boomsma F, Van Den Meiracker AH, Winkel S et al (1999) Circulating semicarbazide-sensitive amine oxidase is raised both in Type I (insulin-dependent), in Type II (non-insulin-dependent) diabetes mellitus and even in childhood Type I diabetes at first clinical diagnosis. Diabetologia. https:\/\/doi.org\/10.1007\/s001250051143","journal-title":"Diabetologia"},{"key":"9716_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2008.06.019","author":"MS Lin","year":"2008","unstructured":"Lin MS, Li HY, Wei JN et al (2008) Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.06.019","journal-title":"Clin Biochem"},{"key":"9716_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/10408363.2015.1050714","volume":"83","author":"R Pannecoeck","year":"2017","unstructured":"Pannecoeck R, Serruys D, Benmeridja L et al (2017) Vascular adhesion protein-1: role in human pathology and application as a biomarker. Crit Rev Clin Lab Sci 83:6. https:\/\/doi.org\/10.3109\/10408363.2015.1050714","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9716_CR8","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1073\/pnas.79.9.3024","volume":"79","author":"A Grubb","year":"1982","unstructured":"Grubb A, L\u00f6fberg H (1982) Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci USA 79:3024\u20133027. https:\/\/doi.org\/10.1073\/pnas.79.9.3024","journal-title":"Proc Natl Acad Sci USA"},{"key":"9716_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/00365518509160980","volume":"45","author":"O Simonsen","year":"1985","unstructured":"Simonsen O, Grubb A, Thysell H (1985) The blood serum concentration of cystatin c (\u03b3trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45:97\u2013101. https:\/\/doi.org\/10.3109\/00365518509160980","journal-title":"Scand J Clin Lab Invest"},{"key":"9716_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4137\/CMED.S12633","volume":"6","author":"HS Assal","year":"2013","unstructured":"Assal HS, Tawfeek S, Rasheed EA et al (2013) Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diab 6:7\u201313. https:\/\/doi.org\/10.4137\/CMED.S12633","journal-title":"Clin Med Insights Endocrinol Diab"},{"key":"9716_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00467-014-2888-2.Urinary","volume":"30","author":"S-Y Lee","year":"2016","unstructured":"Lee S-Y, Choi ME (2016) Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol 30:1063\u20131075. https:\/\/doi.org\/10.1007\/s00467-014-2888-2.Urinary","journal-title":"Pediatr Nephrol"},{"key":"9716_CR12","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1681\/ASN.2014121193","volume":"27","author":"AM Suchy-Dicey","year":"2016","unstructured":"Suchy-Dicey AM, Laha T, Hoofnagle A et al (2016) Tubular secretion in CKD. J Am Soc Nephrol 27:2148\u20132155. https:\/\/doi.org\/10.1681\/ASN.2014121193","journal-title":"J Am Soc Nephrol"},{"key":"9716_CR13","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development\u2014Part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38. https:\/\/doi.org\/10.1038\/psp.2013.14","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9716_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.pharmtox.47.120505.105154","volume":"47","author":"M Danhof","year":"2007","unstructured":"Danhof M, de Jongh J, De Lange ECM et al (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357\u2013400. https:\/\/doi.org\/10.1146\/annurev.pharmtox.47.120505.105154","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9716_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2133\/dmpk.24.3","volume":"24","author":"PP Modeling","year":"2009","unstructured":"Modeling PP (2009) Review incorporating receptor theory in mechanism-based. Distribution 24:3\u201315. https:\/\/doi.org\/10.2133\/dmpk.24.3","journal-title":"Distribution"},{"key":"9716_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/psp4.12049","volume":"5","author":"S Marshall","year":"2016","unstructured":"Marshall S, Burghaus R, Cosson V et al (2016) Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol 5:93\u2013122. https:\/\/doi.org\/10.1002\/psp4.12049","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9716_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248.Estimating","volume":"367","author":"LA Inker","year":"2015","unstructured":"Inker LA, Schmid CH, Tighiouart H et al (2015) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248.Estimating","journal-title":"N Engl J Med"},{"key":"9716_CR18","unstructured":"Holford NHG (2005) The visual predictive check\u2014superiority to standard diagnostic (Rorschach) plots. Abstr"},{"key":"9716_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9081-1","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. https:\/\/doi.org\/10.1007\/s10928-007-9081-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9716_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41581-018-0048-9","volume":"28","author":"MG Koopman","year":"1985","unstructured":"Koopman MG, Krediet RT, Arisz L (1985) Circadian rhythms and the kidney. Neth J Med 28:416\u2013423. https:\/\/doi.org\/10.1038\/s41581-018-0048-9","journal-title":"Neth J Med"},{"key":"9716_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1523-1755.2002.00092.x","volume":"61","author":"HP Hansen","year":"2002","unstructured":"Hansen HP, Hovind P, Jensen BR, Parving H-H (2002) Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy. Kidney Int 61:163\u2013168. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00092.x","journal-title":"Kidney Int"},{"key":"9716_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-020-09716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-020-09716-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-020-09716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T01:26:17Z","timestamp":1631582777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-020-09716-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["9716"],"URL":"https:\/\/doi.org\/10.1007\/s10928-020-09716-x","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"19 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sven Hoefman, Nelleke Snelder and Martijn van Noort are consultants at LAP&P. Alberto Garcia-Hernandez, Hartmut Onkels, Tobias E. Larsson, Kirsten R. Bergmann are former employees of Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}